A novel oral inhibitor for one-carbon metabolism and checkpoint kinase 1 inhibitor as a rational combination treatment for breast cancer

Therapeutic targeting of the mitochondrial one-carbon pathway: perspectives, pitfalls, and potential

(2021) Li Na Zhao et al.   ONCOGENE

Cell cycle control in cancer

(2021) Helen K. Matthews et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

The membrane-linked adaptor FRS2β fashions a cytokine-rich inflammatory microenvironment that promotes breast cancer carcinogenesis

(2021) Yasuto Takeuchi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cancer statistics, 2020

(2020) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Synthetic Lethality with Trifluridine/Tipiracil and Checkpoint Kinase 1 Inhibitor for Esophageal Squamous Cell Carcinoma

(2020) Shinya Ohashi et al.   MOLECULAR CANCER THERAPEUTICS

More Than a Metabolic Enzyme: MTHFD2 as a Novel Target for Anticancer Therapy?

(2020) Zhiyuan Zhu et al.   Frontiers in Oncology

Resistance to the CHK1 inhibitor prexasertib involves functionally distinct CHK1 activities in BRCA wild-type ovarian cancer

(2020) Jayakumar Nair et al.   ONCOGENE

A Phase II Single Arm Pilot Study of the CHK1 Inhibitor Prexasertib ( LY2606368 ) in BRCA Wild‐Type , Advanced Triple‐Negative Breast Cancer

(2020) Margaret E. Gatti‐Mays et al.   ONCOLOGIST

MCM10 compensates for Myc‐induced DNA replication stress in breast cancer stem‐like cells

(2020) Takahiko Murayama et al.   CANCER SCIENCE

Structure-Based Design and Synthesis of an Isozyme-Selective MTHFD2 Inhibitor with a Tricyclic Coumarin Scaffold

(2019) Junya Kawai et al.   ACS Medicinal Chemistry Letters

Efficacy and safety of neoadjuvant chemotherapy regimens for triple-negative breast cancer: a network meta-analysis

(2019) Yunhai Li et al.   Aging-US

Discovery of a Potent, Selective, and Orally Available MTHFD2 Inhibitor (DS18561882) with in Vivo Antitumor Activity

(2019) Junya Kawai et al.   JOURNAL OF MEDICINAL CHEMISTRY

A dose-finding study of the checkpoint kinase 1 inhibitor, prexasertib, in Japanese patients with advanced solid tumors

(2018) Satoru Iwasa et al.   CANCER SCIENCE

Cancer stem-like properties and gefitinib resistance are dependent on purine synthetic metabolism mediated by the mitochondrial enzyme MTHFD2

(2018) Tatsunori Nishimura et al.   ONCOGENE

Semaphorin signaling via MICAL3 induces symmetric cell division to expand breast cancer stem-like cells

(2018) Kana Tominaga et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Reversal of Cytosolic One-Carbon Flux Compensates for Loss of the Mitochondrial Folate Pathway

(2016) Gregory S. Ducker et al.   Cell Metabolism

Behavior of replication origins in Eukaryota – spatio-temporal dynamics of licensing and firing

(2015) Marcelina W Musiałek et al.   CELL CYCLE

Metabolic enzyme expression highlights a key role for MTHFD2 and the mitochondrial folate pathway in cancer

(2014) Roland Nilsson et al.   Nature Communications

Overexpression of the Mitochondrial Folate and Glycine-Serine Pathway: A New Determinant of Methotrexate Selectivity in Tumors

(2012) A. Vazquez et al.   CANCER RESEARCH

The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups

(2012) Christina Curtis et al.   NATURE

Compartmentalization of Mammalian Folate-Mediated One-Carbon Metabolism

(2010) Anne S. Tibbetts et al.   Annual Review of Nutrition

Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method

(2010) T.-C. Chou   CANCER RESEARCH

Subtle variations in Pten dose determine cancer susceptibility

(2010) Andrea Alimonti et al.   NATURE GENETICS